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tion, pain and overall HRQL with patients reporting more mor-
bidity. The results are consistent with the published literature.
Future research should focus on intra-rater reliability, respon-
siveness and validity.
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PRO data have now become an integral part of clinical trials to
evaluate the efﬁcacy of treatment for severe and terminal illness.
However, it is often fraught with missing data due to illness,
death and early termination of a trial (time to event study or
superior efﬁcacy). OBJECTIVES: To evaluate different methods
of data imputation when trials are terminated early and there is
missing data due to deteriorating health. METHODS: Using data
from a large cancer (multiple myeloma) trial which included 
both missing data due to illness and early termination due to
study termination or non-illness-related reasons, several statisti-
cal methods were evaluated. A total of 598 subjects completed
the EORTC QLQ-C30 at least one post-baseline timepoint and
were available for analysis. After setting PRO scores of all sub-
jects who died to the worst possible scores, remaining missing
data were imputed and analyzed by either multiple imputation
(M = 4) using a generalized estimating equation technique, Sun
and Song method for censored data, and Pattern-Mixture
models. Global Health was the primary PRO endpoint with all
other scales adjusted for multiplicity using the Hochberg-
Benjamini method. RESULTS: All methods found similar results,
although the multiple imputation method found the most
number of scales/symptoms signiﬁcant (N = 10). Sun and Song
and the Pattern-Mixture model each found the same four scales/
symptoms signiﬁcantly different between groups—Global
Health, Cognitive Functioning, Emotional Functioning and
Dyspnea. CONCLUSIONS: All methods are useful approaches
to handle missing data imputation and analysis. The multiple
imputation method appears to be less conservative, ﬁnding ten
signiﬁcant differences versus four with the other methods. The
Sun and Song approach provides an insight into what the treat-
ment differences would have been had all the subjects stayed in
the study. The Pattern-Mixture model was the most complex
method and did not provide any additional information over the
other methods.
PCN25
RELIABILITY AND VALIDITY OF BRAZILIAN PORTUGUESE
HEALTH UTILITIES INDEX (HUI) QUESTIONNAIRES FOR
ASSESSING THE HEALTH STATUS OF SURVIVORS OF
CHILDHOOD CANCER
Horsman JR1, Shimoda S2, Furlong W1, Barr RD3
1McMaster University, Hamilton, ON, Canada; 2Centro de 
Tratamento e Pesquisa Hospital do Cancer, Sao Paulo, SP, Brazil;
3Hamilton Health Sciences, McMaster University, Hamilton, ON,
Canada
OBJECTIVES: To assess inter-rater reliability and discriminative
validity of Brazilian Portuguese HUI questionnaires for a sample
of survivors of childhood cancer. METHODS: A sample of 
consecutive patients attending the long-term follow-up clinic 
at Centro de Treatmento e Pesquisa Hospital do Cancer in 
São Paulo was recruited. Self- and proxy-assessment versions of
self-complete, one-week health-status recall HUI questionnaires
were used. A questionnaire was completed independently by
each patient (self-assessment), and nurse and physician (proxy-
assessments). HUI single-attribute utility scores (n = 14) and
health-related quality of life (HRQL) scores (n = 2) were derived
using standard coding algorithms and published utility functions.
Single measure, one-way random effects models were used to cal-
culate intra-class correlations (ICC) of inter-rater agreement.
Analysis of variance (ANOVA) assessed the statistical signiﬁ-
cance (p < 0.05) of differences in mean utility scores for patients
in various diagnostic groups (n = 15). RESULTS: HUI data for
138 cancer survivors (45.7% female) were collected from the
three types of assessors. Patient mean age at diagnosis was 6.3
(min = 0.2, max = 17.4) years and 22.8 (13.4, 40.2) years at
survey. There was substantial to almost perfect agreement 
(ICC > 0.85, p < 0.001) between all pairs of raters for all types
of utility scores. ANOVA detected statistically signiﬁcant (p <
0.013) differences among the diagnostic groups, in means of
HUI2 and HUI3 HRQL utility scores, HUI3 vision (p < 0.0005),
HUI3 ambulation (p = 0.002), HUI2 mobility (p = 0.001) and
HUI2 self-care (p < 0.045). CONCLUSIONS: There was sub-
stantial or better agreement in all single-attribute and HRQL
utility scores between pairs of patient, nurse and physician asses-
sors. Differences in mean HRQL among diagnostic groups is evi-
dence of discriminative validity. The Brazilian Portuguese HUI
questionnaires should be considered for future PRO-studies of
morbidity and HRQL in survivors of cancer in childhood in
Brazil. Future research on the measurement properties of the
Brazilian Portuguese HUI questionnaires should focus on con-
current validity and other health problems.
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OBJECTIVES: The importance of postmarketing surveillance
was again publicized by the recent recall of Vioxx; similar 
concerns should be addressed in trial-based cost-effectiveness
analyses (CEA). The net beneﬁt regression approach applies
econometric methods; thus, offers a power tool to assess CEA of
a new intervention in a non-randomized environment (e.g.,
claims data). Our study proposed a Bayesian approach to syn-
thesize clinical trial data with secondary data collected in post-
marketing setting. METHODS: We ﬁrst compared the treatment
effect estimated from least squares (LS) and Bayesian regressions
using a simulated data of 200 pairs of case-control patients. The
data contained information on cost (C), effectiveness (E), and
demographics for each patient, with 85% of data in the quad-
rant of positive incremental cost and incremental effectiveness.
The dependent variable was the net beneﬁt (NB), calculated as:
lE - C, where l denoted the maximum willingness to pay;
covariates included demographics and a binary variable indicat-
ing treatment. By incorporating trial data in the prior distribu-
tion, we demonstrated use of the Bayesian regression to update
the net beneﬁt estimates with observed data, exempliﬁed by the
simulated data. RESULTS: NB estimated from LS and Bayesian
approaches were very similar when non-informative prior was
used, representing the scenario where the trial data was
neglected. However, using the posterior distribution of the
regression coefﬁcients, the Bayesian approach can infer the prob-
ability that the new treatment was cost-effective. At l = $15,000,
the estimated NB was $679.3 (P = 0.766) in OLS and $677.5 in
Bayesian, with 0.61 probability of cost-effective. When a strong
prior favoring the new treatment was employed, the estimated
NB increased to $3,414 at l = $15,000 and the probability of
